232 related articles for article (PubMed ID: 27696244)
21. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
Esposito NN; Mohan D; Brufsky A; Lin Y; Kapali M; Dabbs DJ
Arch Pathol Lab Med; 2006 Oct; 130(10):1516-21. PubMed ID: 17090194
[TBL] [Abstract][Full Text] [Related]
22. An approach to malignant mammary phyllodes tumors detection.
Ilić I; Randelović P; Ilić R; Katić V; Milentijević M; Velicković L; Krstić M
Vojnosanit Pregl; 2009 Apr; 66(4):277-82. PubMed ID: 19441158
[TBL] [Abstract][Full Text] [Related]
23. Expression of biomarkers in the AKT pathway correlates with malignancy and recurrence in phyllodes tumours of the breast.
Li J; Ho WY; Tsang JYS; Ni YB; Chan SK; Tse GM
Histopathology; 2019 Mar; 74(4):567-577. PubMed ID: 30383904
[TBL] [Abstract][Full Text] [Related]
24. Ki67 and P53 Expression in Relation to Clinicopathological Features in Phyllodes Tumour of the Breast.
Mohd Ali NA; Nasaruddin AF; Mohamed SS; Wan Rahman WF
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2653-2659. PubMed ID: 32986365
[TBL] [Abstract][Full Text] [Related]
25. Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.
Cha YJ; Koo JS
PLoS One; 2020; 15(8):e0238466. PubMed ID: 32857809
[TBL] [Abstract][Full Text] [Related]
26. Recurrence prediction for breast phyllodes tumours: validation of the Singapore nomogram in Korean women.
Choi JE; Kang SH; Tan PH; Bae YK
J Clin Pathol; 2022 Mar; 75(3):159-163. PubMed ID: 33376198
[TBL] [Abstract][Full Text] [Related]
27. Involvement of α- and β-catenins and E-cadherin in the development of mammary phyllodes tumours.
Tsang JY; Mendoza P; Lam CC; Yu AM; Putti TC; Karim RZ; Scolyer RA; Lee CS; Tan PH; Tse GM
Histopathology; 2012 Oct; 61(4):667-74. PubMed ID: 22571452
[TBL] [Abstract][Full Text] [Related]
28. Stromal matrix metalloproteinase-14 expression correlates with the grade and biological behavior of mammary phyllodes tumors.
Kim GE; Kim JH; Lee KH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):298-303. PubMed ID: 22505012
[TBL] [Abstract][Full Text] [Related]
29. Expression of CAF-Related Proteins Is Associated with Histologic Grade of Breast Phyllodes Tumor.
Kim HM; Lee YK; Koo JS
Dis Markers; 2016; 2016():4218989. PubMed ID: 27881889
[No Abstract] [Full Text] [Related]
30. Increased c-kit (CD117) expression in malignant mammary phyllodes tumors.
Tse GM; Putti TC; Lui PC; Lo AW; Scolyer RA; Law BK; Karim R; Lee CS
Mod Pathol; 2004 Jul; 17(7):827-31. PubMed ID: 15044924
[TBL] [Abstract][Full Text] [Related]
31. Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit.
Sawyer EJ; Poulsom R; Hunt FT; Jeffery R; Elia G; Ellis IO; Ellis P; Tomlinson IP; Hanby AM
J Pathol; 2003 May; 200(1):59-64. PubMed ID: 12692842
[TBL] [Abstract][Full Text] [Related]
32. Stem cell biomarker ALDH1A1 in breast cancer shows an association with prognosis and clinicopathological variables that is highly cut-off dependent.
Sjöström M; Hartman L; Honeth G; Grabau D; Malmström P; Hegardt C; Fernö M; Niméus E
J Clin Pathol; 2015 Dec; 68(12):1012-9. PubMed ID: 26175266
[TBL] [Abstract][Full Text] [Related]
33. IMP3 Is Strongly Expressed in Malignant Phyllodes Tumors of the Breast: An Immunohistochemical Study.
Bellezza G; Prosperi E; Del Sordo R; Colella R; Rulli A; Sidoni A
Int J Surg Pathol; 2016 Feb; 24(1):37-42. PubMed ID: 26353850
[TBL] [Abstract][Full Text] [Related]
34. Phyllodes tumour of the breast: immunohistochemical study of 37 tumours using MIB1 antibody.
Kocová L; Skálová A; Fakan F; Rousarová M
Pathol Res Pract; 1998; 194(2):97-104. PubMed ID: 9584322
[TBL] [Abstract][Full Text] [Related]
35. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
[TBL] [Abstract][Full Text] [Related]
36. Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon.
Djordjevic B; Hanna WM
Mod Pathol; 2008 Oct; 21(10):1238-45. PubMed ID: 18500266
[TBL] [Abstract][Full Text] [Related]
37. Phyllodes Tumor of the Breast: Histopathologic Features, Differential Diagnosis, and Molecular/Genetic Updates.
Zhang Y; Kleer CG
Arch Pathol Lab Med; 2016 Jul; 140(7):665-71. PubMed ID: 27362571
[TBL] [Abstract][Full Text] [Related]
38. Survey of recurrent diagnostic challenges in breast phyllodes tumours.
Tan BY; Fox SB; Lakhani SR; Tan PH
Histopathology; 2023 Jan; 82(1):95-105. PubMed ID: 36468287
[TBL] [Abstract][Full Text] [Related]
39. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features.
Shpitz B; Bomstein Y; Sternberg A; Klein E; Tiomkin V; Kaufman A; Groisman G; Bernheim J
J Surg Oncol; 2002 Feb; 79(2):86-92. PubMed ID: 11815995
[TBL] [Abstract][Full Text] [Related]
40. Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors.
Kuijper A; de Vos RA; Lagendijk JH; van der Wall E; van Diest PJ
Am J Clin Pathol; 2005 May; 123(5):690-8. PubMed ID: 15981808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
